国际呼吸杂志
國際呼吸雜誌
국제호흡잡지
INTERNATIONAL JOURNAL OF RESPIRATION
2011年
2期
99-102
,共4页
头孢吡肟%铜绿假单胞菌%AmpC β-内酰胺酶
頭孢吡肟%銅綠假單胞菌%AmpC β-內酰胺酶
두포필우%동록가단포균%AmpC β-내선알매
Cefepime%Pseudomonas aeruginosa%AmpC β-lactamase
目的 评价头孢吡肟对产质粒介导AmpC酶铜绿假单胞菌感染治疗效果.方法 选取产质粒介导AmpC酶铜绿假单胞菌3株,建立大鼠肺炎模型.3株菌体外药物敏感试验对头孢他啶均耐药,第1株菌对头孢吡肟敏感(MIC=4 mg/L),第2株对头孢吡肟在敏感折点(MIC=8 mg/L),第3株菌对头孢吡肟耐药(MIC=16 mg/L),每组设2个亚组(头孢吡肟亚组和生理盐水对照亚组),治疗96 h后评价治疗效果.结果 第1组头孢吡肟亚组生存率(80.8%)高于后两组(61.5%、50.0%)和生理盐水对照亚组(34.6%),肺组织匀浆菌落计数(10.3±3.2)低于后两组(12.0±2.6、12.1±1.8)和生理盐水对照亚组(15.3±4.9)(P值均＜0.05).第2组头孢吡肟亚组生存率(61.5%)高于第3组(50.0%)和生理盐水对照亚组(30.8%),肺组织匀浆菌落计数(12.0±2.6)低于生理盐水对照亚组(16.0±5.5)(P值均＜0.05).结论 体外药敏试验中头孢吡肟在敏感折点MIC=8 mg/L时对大鼠肺炎模型的治疗效果明显低于MIC＜8 μg/ml的治疗效果.
目的 評價頭孢吡肟對產質粒介導AmpC酶銅綠假單胞菌感染治療效果.方法 選取產質粒介導AmpC酶銅綠假單胞菌3株,建立大鼠肺炎模型.3株菌體外藥物敏感試驗對頭孢他啶均耐藥,第1株菌對頭孢吡肟敏感(MIC=4 mg/L),第2株對頭孢吡肟在敏感摺點(MIC=8 mg/L),第3株菌對頭孢吡肟耐藥(MIC=16 mg/L),每組設2箇亞組(頭孢吡肟亞組和生理鹽水對照亞組),治療96 h後評價治療效果.結果 第1組頭孢吡肟亞組生存率(80.8%)高于後兩組(61.5%、50.0%)和生理鹽水對照亞組(34.6%),肺組織勻漿菌落計數(10.3±3.2)低于後兩組(12.0±2.6、12.1±1.8)和生理鹽水對照亞組(15.3±4.9)(P值均＜0.05).第2組頭孢吡肟亞組生存率(61.5%)高于第3組(50.0%)和生理鹽水對照亞組(30.8%),肺組織勻漿菌落計數(12.0±2.6)低于生理鹽水對照亞組(16.0±5.5)(P值均＜0.05).結論 體外藥敏試驗中頭孢吡肟在敏感摺點MIC=8 mg/L時對大鼠肺炎模型的治療效果明顯低于MIC＜8 μg/ml的治療效果.
목적 평개두포필우대산질립개도AmpC매동록가단포균감염치료효과.방법 선취산질립개도AmpC매동록가단포균3주,건립대서폐염모형.3주균체외약물민감시험대두포타정균내약,제1주균대두포필우민감(MIC=4 mg/L),제2주대두포필우재민감절점(MIC=8 mg/L),제3주균대두포필우내약(MIC=16 mg/L),매조설2개아조(두포필우아조화생리염수대조아조),치료96 h후평개치료효과.결과 제1조두포필우아조생존솔(80.8%)고우후량조(61.5%、50.0%)화생리염수대조아조(34.6%),폐조직균장균락계수(10.3±3.2)저우후량조(12.0±2.6、12.1±1.8)화생리염수대조아조(15.3±4.9)(P치균＜0.05).제2조두포필우아조생존솔(61.5%)고우제3조(50.0%)화생리염수대조아조(30.8%),폐조직균장균락계수(12.0±2.6)저우생리염수대조아조(16.0±5.5)(P치균＜0.05).결론 체외약민시험중두포필우재민감절점MIC=8 mg/L시대대서폐염모형적치료효과명현저우MIC＜8 μg/ml적치료효과.
Objective To investigate the efficacy of cefepime on pneumonia caused by Pseudomonas aeruginosa producing plasmid AmpC β-lactamase. Methods Three strains of Pseudomonas aeruginosa were used to make pneumonia rat model. The drug sensitivity test showed that three strains were all resistant to ceftazidime. The first strain was sensitive to cefepime (MIC=4 mg/L), the sensitivity of the second strain to cefepime was at turning point (MIC=8 mg/L), the third strain was resistant to cefepime (MIC=16 mg/L). Each group was divided into two subgroups: cefepime subgroup and normal sodium subgroup. The efficacy was evaluated at 96 h after treatment. Results In the first group, the survival rate in cefepime subgroup (80. 8 % )was higher than that in other two groups (61.5 %, 50.0% ) and normal sodium subgroup (34.6%), the bacterial count in cefepime subgroup (10. 3±3. 2) was lower than that in other two groups ( 12.0± 2.6,12. 1 ±1.8) and normal sodium subgroup ( 15.3 ± 4.9) (all P ＜0. 05). In the second group, the survival rate in cefepime subgroup (61.5 % )was higher than that in the third group (50. 0 % ) and normal sodium subgroup (30.8 % ), the bacterial count in cefepime subgroup ( 12.0 ± 2.6)was lower than that in normal sodium subgroup (16.0±5.5) (all P ＜0.05). Conclusions The efficacy of cefepime on pneumonia rats at MIC=8 mg/L is lower than that at MIC＜8 mg/L.
